2026 · 1st Quarter (Jan 1 - Mar 31)

PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Filing UUID: 7e2590e2-d1de-4a9b-b923-03beef7e2373
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical tariffs and related trade agreements.

MMM · Medicare/Medicaid

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Literal federal measure citations: H.R. 1

HCR · Health Issues

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.